Andrew Penn, Mary Cosimano
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Dr. Phelps discusses current training strategies for practitioners in psychedelic-assisted interventions, focusing on academic standards, ethical guidelines, and the importance of skilled facilitators for positive outcomes. Prioritizing high-quality training standards
Victor Cabral, Kelley O’Donnell, Janis Phelps, Genessee Herzberg
Drs. Summergrad and Insel reflect on the progress and remaining questions in psychedelic science since 2017. They delve into topics like efficacy, regulation, therapy, and provider experience.
Paul Summergrad, Tom Insel, Rachel Nuwer
Rick Doblin discusses growing up with the "queen of psychedelics", Rock and Cosmo's paths to this work, challenges of working with family, and their shared vision for the psychedelic renaissance.
Amanda Feilding, Rock Feilding-Mellen, Cosmo Fielding Mellen
Panel discusses LGBT+ perspectives on psychedelic therapy, emphasizing community's healing role. Recommendations for queer-inclusive therapy and research draw from queer history, including AIDS crisis and conversion therapy.
Alex Belser, Clancy Cavnar
Artificial Intelligence and psychedelics share complexities as powerful tools impacting humanity's reality and choices. Understanding their potential and regulating them ethically are urgent imperatives for positive impact.
Alexander Beiner, De Kai
Traditional cultures use psychedelics, but companies are patenting therapies and compounds based on them. Discussion explores IP system improvements for innovation and public health protection.
Chris Byrnes, Laurel Kilgour, Leslie Booher
Imran Khan presents findings of the Psychedelic Insight Poll, a national survey by the Berkeley Center for the Science of Psychedelics to understand public perceptions of psychedelic substances. The poll
Imran Khan
Funding for psychedelic medicine is evolving, with a rise in commercial capital alongside philanthropic support. Balancing financial interests with equitable access and learning from scaling challenges are key considerations.
Henry Elkus
NIMH Director Joshua A. Gordon and trauma researcher Barbara O. Rothbaum discuss the current state and future directions of psychedelic research, emphasizing the need for deeper understanding and robust study
Joshua A Gordon
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.